See full prescribing & safety info. Kisqali was developed by novartis under a research collaboration with astex pharmaceuticals. Kisqali affects cancer cells, but can also affect healthy cells.
Naked
Ribociclib (kisqali) was fda approved in 2017 in combination with endocrine therapy for er+, metastatic breast cancer.
